Inforlife Company Profile

What is the competitive landscape for INFORLIFE

INFORLIFE has eleven approved drugs.

There are two US patents protecting INFORLIFE drugs.

There is one patent family member on INFORLIFE drugs in one country and fourteen supplementary protection certificates in six countries.

Summary for Inforlife

International Patents:	1
US Patents:	2
Tradenames:	11
Ingredients:	10
NDAs:	11

Drugs and US Patents for Inforlife

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Inforlife	ACETAMINOPHEN	acetaminophen	SOLUTION;INTRAVENOUS	215403-001	May 3, 2023	AP	RX	No	No
Inforlife	MIDAZOLAM IN 0.9% SODIUM CHLORIDE	midazolam	SOLUTION;INTRAVENOUS	211844-002	Mar 22, 2021	AP	RX	Yes	Yes	10,966,990		Y
Inforlife	LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER	levofloxacin	INJECTABLE;INJECTION	090343-002	Jul 7, 2011	AP	RX	No	Yes
Inforlife	NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE	nicardipine hydrochloride	INJECTABLE;INTRAVENOUS	203978-001	Apr 17, 2024	AP	RX	No	No
Inforlife	METRONIDAZOLE IN PLASTIC CONTAINER	metronidazole	INJECTABLE;INJECTION	206191-001	Feb 25, 2019	AP	RX	No	No

International Patents for Inforlife Drugs

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2020217079

Supplementary Protection Certificates for Inforlife Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0206283	SPC/GB97/085	United Kingdom		PRODUCT NAME: LEVOFLOXACIN, OPTIONALLY IN THE FORM OF A HEMIHYDRATE; REGISTERED: UK 13402/0011 19970606; UK 13402/0012 19970606; UK 13402/0013 19970606
1429780	13C0012	France		PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808
0206283	98C0041	Belgium		PRODUCT NAME: LEVOFLOXACINUM HEMIHYDRICUM; NAT. REGISTRATION NO/DATE: 354 IS 370 F3 19980624; FIRST REGISTRATION: GB 134020011 19970606
1429780	132013902137451	Italy		PRODUCT NAME: CIPROFLOXACINA E DESAMETASONE(CILODEX); AUTHORISATION NUMBER(S) AND DATE(S): 48976, 20120810;041182015/M, 20121106
0239710	SPC/GB96/051	United Kingdom		PRODUCT NAME: (S)-(-)-1-PROPYL-2',6'-PIPECOLOXYLIDIDE HYDROCHLORIDE MONOHYDRATE (GENERIC NAME: ROPIVACAINE MONOHYDROCHLORIDE MONOHYDRATE); REGISTERED: SE 12319 19950915; SE 12322 19950915; SE 12323 19950915; UK 0017/0375 19960517; UK 0017/0376 19960517; UK 0017/0377 19960517; UK 0017/0378 19960517

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Inforlife

Pharmaceutical Competitive Landscape Analysis: InfoRLife – Market Position, Strengths & Strategic Insights

In the ever-evolving pharmaceutical industry, staying ahead of the competition is crucial for success. InfoRLife, a subsidiary of ACS Dobfar, has carved out a unique position in the market, specializing in the development, registration, and production of ready-to-use medicines. This article delves into InfoRLife's market position, strengths, and strategic insights, providing a comprehensive competitive landscape analysis.

InfoRLife: A Brief Overview

InfoRLife is a pharmaceutical company with its main facility located in Brusio, Switzerland. As a subsidiary of ACS Dobfar, InfoRLife benefits from the resources and expertise of its parent company, which is a global leader in antibiotic production[1].

Key Facts:

• Founded: January 8, 2002[10]
• Headquarters: Brusio, Switzerland
• Specialization: Ready-to-use medicines
• Parent Company: ACS Dobfar

Market Position and Product Portfolio

InfoRLife has established a strong presence in the pharmaceutical market, particularly in the production of intravenous antibiotics. The company's product portfolio is designed to meet the needs of hospitals across the Nordic countries[1].

Nordic Market Presence

InfoRLife's acquisition of marketing authorizations for antibiotics in the Nordic region has solidified its position in this market. The annual tender-based turnover for these products is approximately NOK 25 million, indicating a significant market share[1].

Product Focus

The company specializes in:

1. Intravenous antibiotics
2. Ready-to-use medicines
3. Sterile products in plastic bags

Manufacturing Capabilities and Approvals

InfoRLife's manufacturing capabilities are a key strength in its competitive positioning.

FDA Approval

The company has received approval from the U.S. Food and Drug Administration (FDA) for sales in the USA, which is its main market[1]. This approval underscores the quality and reliability of InfoRLife's products and manufacturing processes.

Sterile Manufacturing Expertise

InfoRLife is specialized in the manufacture of medicines in plastic bags using sterile methods and technology. This expertise sets the company apart in the production of high-quality, ready-to-use pharmaceutical products[1].

Research and Development

Innovation is at the heart of InfoRLife's strategy. The company develops all its new products in its own R&D laboratories, ensuring a pipeline of innovative medicines[1].

Global Presence

While the Nordic countries and the USA are key markets for InfoRLife, the company's reach extends beyond these regions.

Subsidiaries

InfoRLife controls three subsidiaries located in:

1. Romania
2. Tunisia
3. Brazil

This global presence allows the company to tap into diverse markets and leverage different regional strengths[1].

Competitive Advantages

InfoRLife's competitive advantages stem from its specialized focus, manufacturing expertise, and strategic partnerships.

1. Specialized Product Range

By focusing on ready-to-use medicines and intravenous antibiotics, InfoRLife has carved out a niche in the pharmaceutical market. This specialization allows the company to excel in its chosen areas of focus.

2. Quality Manufacturing

The FDA approval for the U.S. market is a testament to InfoRLife's high-quality manufacturing processes. This approval opens doors to one of the world's largest pharmaceutical markets and enhances the company's credibility globally.

3. Strategic Partnerships

InfoRLife's position as a subsidiary of ACS Dobfar provides it with significant advantages. ACS Dobfar, a global leader in antibiotic production, brings valuable resources, expertise, and market access to InfoRLife[1].

Market Trends and Opportunities

Understanding market trends is crucial for maintaining a competitive edge. Several trends in the pharmaceutical industry present opportunities for InfoRLife.

1. Growing Demand for Antibiotics

The global demand for antibiotics remains strong, particularly in hospital settings. InfoRLife's focus on intravenous antibiotics positions it well to capitalize on this demand.

2. Emphasis on Ready-to-Use Medicines

Healthcare providers are increasingly seeking ready-to-use medicines to improve efficiency and reduce the risk of medication errors. InfoRLife's expertise in this area aligns well with this trend.

3. Focus on Supply Chain Security

"Drug shortage is an important issue in the Nordics. By combining Navamedic's local expertise with products from a reliable European manufacturer, the transaction is also important to secure steady supply of key products to Nordic hospitals."[1]

This statement from Kathrine Gamborg Andreassen, CEO of Navamedic, highlights the growing importance of supply chain security in the pharmaceutical industry. InfoRLife's European manufacturing base and focus on the Nordic market position it as a reliable supplier in this context.

Competitive Landscape

To fully understand InfoRLife's position, it's essential to consider the broader competitive landscape of the pharmaceutical industry.

Global Pharmaceutical Market

The pharmaceutical industry continues to grow, with the global market estimated to be worth US$1.6 trillion in 2023[2]. This growth presents opportunities for companies like InfoRLife, but also intensifies competition.

Top Players

While InfoRLife operates in a specialized niche, it's important to be aware of the major players in the pharmaceutical industry. As of 2024, the top pharmaceutical companies by revenue include:

1. Pfizer - US$58.5bn
2. Johnson & Johnson - US$54.76bn
3. AbbVie - US$54.32bn
4. Merck & Co - US$53.6bn[2]

While InfoRLife may not compete directly with these giants in all areas, understanding their strategies and market positions can provide valuable insights.

Strategic Insights for InfoRLife

Based on the competitive landscape analysis, several strategic insights emerge for InfoRLife:

1. Leverage Niche Expertise

InfoRLife's specialization in ready-to-use medicines and intravenous antibiotics is a key strength. The company should continue to leverage this expertise, potentially expanding its product range within these niches.

2. Expand Geographic Presence

While the Nordic countries and the USA are key markets, InfoRLife could explore opportunities to expand its presence in other regions, potentially leveraging its existing subsidiaries in Romania, Tunisia, and Brazil.

3. Invest in R&D

Continued investment in research and development is crucial to maintain a competitive edge. InfoRLife should focus on developing innovative products that address unmet medical needs within its areas of expertise.

4. Strengthen Supply Chain

Given the increasing focus on supply chain security in the pharmaceutical industry, InfoRLife should continue to strengthen its manufacturing and distribution capabilities to position itself as a reliable supplier.

5. Explore Strategic Partnerships

While InfoRLife benefits from its relationship with ACS Dobfar, exploring additional strategic partnerships could provide opportunities for growth and market expansion.

Competitive Intelligence Strategies

To maintain and improve its competitive position, InfoRLife should implement robust competitive intelligence strategies.

1. Systematic Competitor Analysis

Regularly analyzing competitors' strengths, weaknesses, and strategies is crucial. This analysis should cover not just direct competitors, but also larger pharmaceutical companies that may impact the market[6].

2. Market Trend Monitoring

Staying abreast of market trends, including changes in healthcare policies, technological advancements, and shifts in patient needs, is essential for informed decision-making[6].

3. Patent Landscape Assessment

In the pharmaceutical industry, patents are crucial. Monitoring the patent landscape can help identify potential opportunities and threats[6].

4. Regulatory Strategy Analysis

Understanding how competitors navigate the complex regulatory landscape can provide valuable insights. This includes monitoring approaches to clinical trials, regulatory submissions, and market access strategies[6].

Future Outlook

The pharmaceutical industry is poised for continued growth and transformation. According to Statista, the global pharmaceuticals market is projected to grow by 4.76% (2025-2029), reaching a market volume of US$1454.00bn in 2029[8].

For InfoRLife, this growth presents both opportunities and challenges. By leveraging its strengths, addressing potential weaknesses, and staying attuned to market trends, InfoRLife can position itself for success in this evolving landscape.

Key Takeaways

1. InfoRLife, a subsidiary of ACS Dobfar, specializes in ready-to-use medicines and intravenous antibiotics.
2. The company has a strong presence in the Nordic countries and FDA approval for the U.S. market.
3. InfoRLife's competitive advantages include its specialized product range, quality manufacturing, and strategic partnerships.
4. Key market trends include growing demand for antibiotics, emphasis on ready-to-use medicines, and focus on supply chain security.
5. Strategic insights for InfoRLife include leveraging niche expertise, expanding geographic presence, investing in R&D, strengthening the supply chain, and exploring strategic partnerships.
6. Implementing robust competitive intelligence strategies is crucial for maintaining a competitive edge in the pharmaceutical industry.
7. The global pharmaceutical market is projected to grow, presenting opportunities for companies like InfoRLife.

FAQs

1. What is InfoRLife's main area of specialization? InfoRLife specializes in the development, registration, and production of ready-to-use medicines, particularly intravenous antibiotics.

2. Where is InfoRLife headquartered? InfoRLife's main facility is located in Brusio, Switzerland.

3. What markets does InfoRLife serve? InfoRLife has a strong presence in the Nordic countries and is approved for sales in the USA. It also has subsidiaries in Romania, Tunisia, and Brazil.

4. How does InfoRLife's relationship with ACS Dobfar benefit the company? As a subsidiary of ACS Dobfar, a global leader in antibiotic production, InfoRLife benefits from its parent company's resources, expertise, and market access.

5. What are some key competitive intelligence strategies for pharmaceutical companies? Key strategies include systematic competitor analysis, market trend monitoring, patent landscape assessment, and regulatory strategy analysis.

Sources cited:

1. https://navamedic.com/news/navamedic-asa-completed-the-acquisition-of-marketing-authorisations-for-antibiotics-in-the-nordics/
2. https://www.proclinical.com/blogs/2024-7/who-are-the-top-10-pharma-companies-in-the-world-2024
3. https://www.infodesk.com/blog/5-steps-to-create-an-effective-pharmaceutical-competitive-intelligence-process/life-sciences
4. https://www.statista.com/outlook/hmo/pharmaceuticals/worldwide
5. https://www.moneyhouse.ch/en/company/inforlife-sa-11771374141